Selenium-containing nanoparticles synergistically enhance Pemetrexed&NK cell-based chemoimmunotherapy.

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Research

Background:

• Natural Killer (NK) cell immunotherapy and pemetrexed (Pem) chemotherapy show promise in cancer treatment.
• Over-expressed NK cell inhibitory receptors on cancer cells and low Pem internalization limit clinical efficacy.
• Developing strategies to overcome these limitations is crucial for effective cancer therapy.

Purpose of the Study:

• To construct selenium-containing nanoparticles for synergistic enhancement of pemetrexed chemotherapy and NK cell immunotherapy.
• To investigate the mechanism by which these nanoparticles improve chemotherapy efficiency and activate NK cells.
• To evaluate the in vitro and in vivo efficacy of this chemoimmunotherapy strategy.

Main Methods:

• Synthesis of selenium-containing nanoparticles encapsulating pemetrexed.
• In vitro studies to assess nanoparticle uptake, seleninic acid generation, and NK cell activation.
• In vivo experiments to evaluate tumor suppression and immune response enhancement.
• Analysis of NK cell inhibitory receptor expression modulation.

Main Results:

• Selenium nanoparticles effectively delivered pemetrexed to tumor sites, enhancing chemotherapy efficacy.
• Generated seleninic acid from nanoparticles blocked NK cell inhibitory receptors, activating NK cell activity.
• Demonstrated synergistic chemoimmunotherapy effects in both in vitro and in vivo models.
• Confirmed the potential of seleninic acid in modulating the tumor microenvironment for immune-mediated killing.

Conclusions:

• Selenium-containing nanoparticles offer a promising platform for chemoimmunotherapy by enhancing drug delivery and immune activation.
• Selininic acid plays a key role in overcoming NK cell inhibition and boosting anti-tumor immunity.
• This strategy holds significant potential for improving cancer treatment outcomes through synergistic chemoimmunotherapy.